AIGH Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• AIGH Capital Management purchased 1,998,431 shares of Vanda (≈$17.63M) in Q4, making VNDA about 4.3% of AIGH’s portfolio and the firm's 7th largest holding, while AIGH owns roughly 3.38% of Vanda.
• Analyst sentiment is mixed but leans positive with a consensus rating of "Moderate Buy" (five Buys, two Holds, one Sell) and a consensus price target of $14.90, though individual reports range from HC Wainwright's $24 target to sell ratings from Weiss and Wall Street Zen.
• Vanda reported negative EPS and margins and missed quarterly revenue expectations, trades around $7 with a market cap near $421M, and insiders sold 314,342 shares (~$2.58M) over the last quarter, leaving insiders with about 10% ownership.

AIGH Capital Management LLC purchased a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,998,431 shares of the biopharmaceutical company's stock, valued at approximately $17,626,000. Vanda Pharmaceuticals comprises about 4.3% of AIGH Capital Management LLC's portfolio, making the stock its 7th largest position. AIGH Capital Management LLC owned about 3.38% of Vanda Pharmaceuticals as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Torren Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $25,000. Jane Street Group LLC increased its position in shares of Vanda Pharmaceuticals by 6.1% during the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company's stock worth $373,000 after buying an additional 4,533 shares during the period. Savant Capital LLC increased its position in shares of Vanda Pharmaceuticals by 30.3% during the third quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company's stock worth $112,000 after buying an additional 5,229 shares during the period. Russell Investments Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 5,328 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Vanda Pharmaceuticals by 33.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,413 shares of the biopharmaceutical company's stock worth $190,000 after buying an additional 5,913 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VNDA has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Monday, February 23rd. UBS Group restated a "buy" rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Finally, Zacks Research lowered shares of Vanda Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $14.90.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $7.00 on Friday. The company has a 50 day moving average of $7.58 and a 200 day moving average of $6.74. The stock has a market cap of $420.91 million, a P/E ratio of -1.88 and a beta of 0.65. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $9.94. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The firm had revenue of $57.22 million for the quarter, compared to analysts' expectations of $59.28 million. As a group, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -2.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.17, for a total value of $1,276,439.95. Following the completion of the transaction, the chief executive officer owned 2,704,496 shares of the company's stock, valued at $22,095,732.32. The trade was a 5.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kevin Patrick Moran sold 42,442 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,995.34. Following the completion of the sale, the chief financial officer owned 411,380 shares of the company's stock, valued at approximately $3,402,112.60. The trade was a 9.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 314,342 shares of company stock worth $2,583,985. 10.00% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.